The acquisition of two Chicago-based firms creates a new market for Aprio, reinforces commitment to expanding its position across the U.S. "We are pleased to expand our footprint into the greater ...

At a median follow-up of 53 months, the median PFS was not reached with KRd and was 48.8 months with VRd. Carfilzomib, lenalidomide, and dexamethasone (KRd) significantly prolonged progression-free ...

KRd showed superior PFS and deeper responses compared to VRd in newly diagnosed multiple myeloma patients, achieving higher complete response and MRD-negativity rates. The trial demonstrated ...

“Patients did great” with a four-drug regimen for multiple myeloma, an expert told CURE®. Patients with newly diagnosed multiple myeloma treated with the four-drug combination of Sarclisa (isatuximab) ...

Patients with newly diagnosed multiple myeloma often receive twice-weekly triplet regimens of carfilzomib, lenalidomide, and dexamethasone (KRd). New data suggest less frequent dosing can be equally ...

PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor–Positive ...

New real-world data confirms that carfilzomib, lenalidomide, and dexamethasone (KRd) are a safe and effective option for patients with relapsed or refractory multiple myeloma. A new analysis of the ...

A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).

RIO DE JANEIRO — A quadruplet induction regimen of isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in the treatment of newly diagnosed multiple myeloma (MM) shows a notably high ...

In 2011, a group of experts in different fields like solar photovoltaics, renewable energies, business internationalization, and foreign investments, led by the co-founders: Sergio Cardamas and Oscar ...